Zydus Cadila has received approval from the US health regulator to market ezetimibe tablets used to treat high cholesterol.
The company has received final approval from the USFDA to market ezetimibe tablets USP, 10 mg, Zydus Cadila said in a BSE filing today.
Ezetimibe is a drug used to reduce high cholesterol levels, the company said, adding that it will be produced at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
As per IMS MAT April 2017 data, the ezetimibe tablets have an estimated sales of $2.7 billion, it added.
The group now has around 115 approvals from USFDA and has so far filed 300 abbreviated new drug applications (ANDAs), the company said.
Shares of Cadila Healthcare were trading 0.72 per cent down at Rs 544.40 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.